Tagged with Access,

Mexico Nicolas Linares of Ultragenyx Pharmaceutical Mexico highlights the company’s commitment to developing innovative treatments for rare and ultra-rare diseases. He emphasizes the importance of collaboration with healthcare systems and the need for a focused approach to address the unique challenges faced by patients in Mexico.   By fostering collaboration among…

Switzerland Daniel Weber of Boehringer Ingelheim Switzerland explores the company’s strategic initiatives and focus on innovation within the Swiss healthcare system. Weber emphasizes Boehringer Ingelheim’s long-term vision of transforming lives, its commitment to early diagnosis, and its expanding role in digital health.   Our purpose and strong pipeline are what truly…

Switzerland Johnson & Johnson Innovative Medicine’s Max Pahlow discusses how the company’s commitment to innovation and patient care drives its success in Switzerland. He highlights the importance of advancing clinical trials, digitalization, and modernizing the pricing and reimbursement system to maintain Switzerland’s competitive edge in healthcare.   Switzerland isn’t a lucky…

Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Switzerland Katharina Gasser of Roche Pharma Switzerland lays out her dedication to fostering innovation, strengthening team dynamics, and influencing the future of Switzerland’s healthcare landscape. Gasser emphasizes the need to combat complacency, advance digitalization, and promote diversity in leadership, noting that “complacency is a real threat—it stifles innovation, diminishes drive, and…

Global The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez shares some exclusive insights on where pharma has made significant strides on the important metric of ‘patient reach’ and the…

Global In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step up, and the establishment of some vital institutional structures in the first decade of the millennium, access is up, while…

Africa Leading HIV patient advocate Flavia Kyomukama talks through the evolution of access to HIV treatment and prevention in Uganda over the last 30 years, as well as the challenges that remain, including sustaining the HIV response, combating stigma, and ensuring the prevention of mother-to-child transmission. She touches on some of…

Global Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access to HIV treatment and prevention. Iyer highlights the impact of voluntary licensing of drugs via the Medicines Patent Pool and…

Saudi Arabia Abdul Latif Jameel is one of Saudi Arabia’s most storied distributors, with a history dating back to 1945. Although present in the healthcare space since 1995 via its philanthropic activities, it has only recently moved to set up a dedicated healthcare arm, known as Jameel Health. Led by Big Pharma…